Glioblastoma Multiforme in a Patient with Multiple Myeloma: A Case Report and Literature Review | Zendy

Christine Moore | Zendy; Moayed Ibrahim | Zendy; Aaysha Kapila | Zendy; Kailash Bajaj | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glioblastoma Multiforme in a Patient with Multiple Myeloma: A Case Report and Literature Review

Author(s) -

Christine Moore,

Moayed Ibrahim,

Aaysha Kapila,

Kailash Bajaj

Publication year - 2018

Publication title -

the permanente journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.445

H-Index - 30

eISSN - 1552-5775

pISSN - 1552-5767

DOI - 10.7812/tpp/17-125

Subject(s) - lenalidomide , medicine , multiple myeloma , thalidomide , oncology , myelodysplastic syndromes , nausea , dermatology , bone marrow

Lenalidomide is an immunomodulatory drug approved by the US Food and Drug Administration in 2006 for the treatment of multiple myeloma. In 2012, the Food and Drug Administration issued a statement warning physicians of the increased risk with lenalidomide treatment of the following secondary primary malignancies: Acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma. The statement did not mention glioblastoma multiforme, a Grade 4 astrocytoma, or other high-grade astrocytomas that have been reported on rare occasions in the setting of multiple myeloma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research